Our mission is to be the leading provider of equity research in healthcare and life sciences

We produce institutional­ quality equity research on small/mid­cap healthcare and life sciences companies, making it available to all investors wherever they are based. Our goal is to bring exciting investment ideas to investors, and to assist companies in achieving their objectives.

research-clients

14

Research Clients

reports-published

103

Reports published

readers-in-database

10k+

Readers in database

Merger between @MereoBioPharma and @OncoMed_Pharma has been completed, Mereo to start trading on @Nasdaq tomorrow

Data so far suggests that bemcentinib can enhance activity of pembrolizumab in NSCLC, in particular in PD-L1 negative patients. Also, impressive efficacy has already been seen in Axl-positive AML patients with bemcentinib monotherapy

.@BerGenBio will be presenting OS data from stage 1 of the Phase II NSCLC study with bemcentinib in combination with pembrolizumab, and initial efficacy data from stage 2 and data from the Phase II trial in AML with bemcentinib in combination with chemoat #ASCO19

Another paper which relies upon ANGLE plc's @Parsortix has been published. This time work by @MDAndersonNews on breast cancer has been published in the Nature publication @SciReports
https://t.co/3PE1dejMuz

.@MereoBioPharma is set to start trading on @Nasdaq on 24 April, after @OncoMed_Pharma shareholders voted in favour of the merger yesterday

Acumapimod’s @US_FDA end of Phase II meeting confirms the outline pivotal Phase III clinical trial programme in acute #COPD exacerbations.

Clarity on the path to market could catalyse @MereoBioPharma’s out-licensing discussions. $MPH.L

Read our note at: https://t.co/LTPHitKXWa

Subscribe to our research

Please sign up here to be added to our distribution database